Travere Therapeutics Stock Debt To Equity

TVTX Stock

USD 18.25 0.01 0.05%

Travere Therapeutics fundamentals help investors to digest information that contributes to Travere Therapeutics' financial success or failures. It also enables traders to predict the movement of Travere Stock. The fundamental analysis module provides a way to measure Travere Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Travere Therapeutics stock.

		Last Reported	Projected for Next Year
	Debt To Equity	1.90	2.00

Debt To Equity is likely to rise to 2.00 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Travere Therapeutics Company Debt To Equity Analysis

Travere Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Travere Therapeutics Debt To Equity

2.60 %

Most of Travere Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Travere Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Travere Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Travere Therapeutics is extremely important. It helps to project a fair market value of Travere Stock properly, considering its historical fundamentals such as Debt To Equity. Since Travere Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Travere Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Travere Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Short Term Investments	Net Receivables	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Net Working Capital	Property Plant Equipment	Short Long Term Debt	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.8	0.54	-0.68	0.6	0.85	0.99	0.2	0.94	0.2	0.86	0.96	0.39	-0.29	-0.35	0.72	0.72	0.74	0.37	-0.19	0.59	-0.19	0.53
Total Stockholder Equity	0.8		0.06	-0.22	0.34	0.46	0.75	0.28	0.63	0.49	0.85	0.67	0.6	-0.06	0.09	0.22	0.44	0.42	0.17	-0.07	0.15	-0.07	0.12
Net Debt	0.54	0.06		-0.94	0.79	0.88	0.59	-0.1	0.63	-0.37	0.28	0.71	-0.05	-0.79	-0.91	0.92	0.74	0.74	0.37	-0.69	0.84	-0.69	0.82
Retained Earnings	-0.68	-0.22	-0.94		-0.83	-0.94	-0.73	0.12	-0.78	0.33	-0.38	-0.8	0.03	0.75	0.82	-0.94	-0.8	-0.84	-0.49	0.64	-0.94	0.64	-0.9
Accounts Payable	0.6	0.34	0.79	-0.83		0.81	0.62	0.0	0.66	-0.19	0.43	0.71	0.05	-0.85	-0.76	0.72	0.69	0.68	0.26	-0.8	0.73	-0.8	0.75
Total Liab	0.85	0.46	0.88	-0.94	0.81		0.87	0.08	0.88	-0.09	0.66	0.91	0.15	-0.62	-0.71	0.92	0.81	0.84	0.44	-0.54	0.81	-0.54	0.77
Total Current Assets	0.99	0.75	0.59	-0.73	0.62	0.87		0.1	0.93	0.1	0.78	0.98	0.31	-0.34	-0.39	0.78	0.78	0.81	0.37	-0.22	0.66	-0.22	0.61
Short Term Debt	0.2	0.28	-0.1	0.12	0.0	0.08	0.1		0.22	0.74	0.5	0.04	0.29	0.07	0.16	-0.19	-0.08	-0.12	-0.3	0.06	-0.18	0.06	-0.12
Common Stock	0.94	0.63	0.63	-0.78	0.66	0.88	0.93	0.22		0.14	0.76	0.92	0.35	-0.39	-0.49	0.77	0.68	0.72	0.43	-0.25	0.72	-0.25	0.66
Current Deferred Revenue	0.2	0.49	-0.37	0.33	-0.19	-0.09	0.1	0.74	0.14		0.5	0.01	0.46	0.24	0.36	-0.36	-0.17	-0.23	-0.38	0.2	-0.35	0.2	-0.28
Intangible Assets	0.86	0.85	0.28	-0.38	0.43	0.66	0.78	0.5	0.76	0.5		0.72	0.54	-0.08	-0.14	0.37	0.4	0.4	0.23	-0.09	0.2	-0.09	0.16
Short Term Investments	0.96	0.67	0.71	-0.8	0.71	0.91	0.98	0.04	0.92	0.01	0.72		0.25	-0.46	-0.52	0.86	0.84	0.85	0.35	-0.33	0.72	-0.33	0.68
Net Receivables	0.39	0.6	-0.05	0.03	0.05	0.15	0.31	0.29	0.35	0.46	0.54	0.25		0.01	0.01	-0.06	-0.09	-0.1	0.14	0.0	-0.03	0.0	-0.07
Good Will	-0.29	-0.06	-0.79	0.75	-0.85	-0.62	-0.34	0.07	-0.39	0.24	-0.08	-0.46	0.01		0.81	-0.61	-0.62	-0.56	-0.2	0.95	-0.74	0.95	-0.78
Net Tangible Assets	-0.35	0.09	-0.91	0.82	-0.76	-0.71	-0.39	0.16	-0.49	0.36	-0.14	-0.52	0.01	0.81		-0.78	-0.46	-0.45	-0.3	0.69	-0.75	0.69	-0.74
Long Term Debt	0.72	0.22	0.92	-0.94	0.72	0.92	0.78	-0.19	0.77	-0.36	0.37	0.86	-0.06	-0.61	-0.78		0.83	0.85	0.46	-0.46	0.87	-0.46	0.82
Net Invested Capital	0.72	0.44	0.74	-0.8	0.69	0.81	0.78	-0.08	0.68	-0.17	0.4	0.84	-0.09	-0.62	-0.46	0.83		0.98	0.35	-0.54	0.76	-0.54	0.75
Net Working Capital	0.74	0.42	0.74	-0.84	0.68	0.84	0.81	-0.12	0.72	-0.23	0.4	0.85	-0.1	-0.56	-0.45	0.85	0.98		0.36	-0.49	0.81	-0.49	0.79
Property Plant Equipment	0.37	0.17	0.37	-0.49	0.26	0.44	0.37	-0.3	0.43	-0.38	0.23	0.35	0.14	-0.2	-0.3	0.46	0.35	0.36		-0.18	0.47	-0.18	0.24
Short Long Term Debt	-0.19	-0.07	-0.69	0.64	-0.8	-0.54	-0.22	0.06	-0.25	0.2	-0.09	-0.33	0.0	0.95	0.69	-0.46	-0.54	-0.49	-0.18		-0.59	1.0	-0.64
Capital Stock	0.59	0.15	0.84	-0.94	0.73	0.81	0.66	-0.18	0.72	-0.35	0.2	0.72	-0.03	-0.74	-0.75	0.87	0.76	0.81	0.47	-0.59		-0.59	0.97
Long Term Debt Total	-0.19	-0.07	-0.69	0.64	-0.8	-0.54	-0.22	0.06	-0.25	0.2	-0.09	-0.33	0.0	0.95	0.69	-0.46	-0.54	-0.49	-0.18	1.0	-0.59		-0.64
Capital Surpluse	0.53	0.12	0.82	-0.9	0.75	0.77	0.61	-0.12	0.66	-0.28	0.16	0.68	-0.07	-0.78	-0.74	0.82	0.75	0.79	0.24	-0.64	0.97	-0.64

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Travere Therapeutics

Debt To Equity Over Time

Travere Total Stockholder Equity

Total Stockholder Equity

168.01 Million

At this time, Travere Therapeutics' Total Stockholder Equity is fairly stable compared to the past year.

According to the company disclosure, Travere Therapeutics has a Debt To Equity of 2.604%. This is 95.14% lower than that of the Biotechnology sector and 86.55% lower than that of the Health Care industry. The debt to equity for all United States stocks is 94.65% higher than that of the company.

Travere Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Travere Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics of similar companies.

Travere Therapeutics is currently under evaluation in debt to equity category among its peers.

Travere Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Travere Therapeutics from analyzing Travere Therapeutics' financial statements. These drivers represent accounts that assess Travere Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Travere Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	601.2M	1.3B	1.9B	1.3B	667.7M	572.6M
Enterprise Value	743.7M	1.4B	2.0B	1.7B	1.0B	646.3M

Travere Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Travere Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Travere Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Travere Fundamentals

	Return On Equity	-2.8
	Return On Asset	-0.26
	Profit Margin	(1.73) %
	Operating Margin	(0.89) %
	Current Valuation	1.71 B
	Shares Outstanding	87.03 M
	Shares Owned By Insiders	0.65 %
	Shares Owned By Institutions	98.58 %
	Number Of Shares Shorted	7.99 M
	Price To Book	76.10 X
	Price To Sales	7.81 X
	Revenue	145.24 M
	Gross Profit	(31.35 M)
	EBITDA	(326.25 M)
	Net Income	(376.33 M)
	Cash And Equivalents	553.17 M
	Cash Per Share	8.65 X
	Total Debt	404.78 M
	Debt To Equity	2.60 %
	Current Ratio	4.71 X
	Book Value Per Share	(0.39) X
	Cash Flow From Operations	(280.02 M)
	Short Ratio	3.92 X
	Earnings Per Share	(4.52) X
	Price To Earnings To Growth	(0.02) X
	Target Price	26.94
	Number Of Employees	380
	Beta	0.7
	Market Capitalization	1.59 B
	Total Asset	788.91 M
	Retained Earnings	(1.13 B)
	Working Capital	438.87 M
	Net Asset	788.91 M

About Travere Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Travere Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC